AllerT
Phase 2Small molecule
AllerT is one of 59 small molecule programs targeting Allergy. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
149 competitors in Allergy
#DrugCompanyPhaseTrials
1Flovent
GSKPhase 3
Clarinex
OOrganon and Co
Phase 3
Xolair
RochePhase 2
REGN5715
RegeneronPhase 3
REGN5713
RegeneronPhase 3
Rhapsido
NovartisPhase 2
Ligelizumab
NovartisPhase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 2
Elspar
DDutch Childhood Oncology Group
Phase 2
Adrenaline
SSamson Clinical Operations Pty Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia1 trial
Allergy1 trial
Conjunctivitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AllerT. EMBL-EBI & Wellcome Sanger Institute.
- [4]